Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents

Abstract

PurposeTo compare treatment outcomes, more specifically patency rate, of polymeric and metallic stents for malignant ureteral obstruction.Patients and methodsBetween August 2007 and September 2017, we retrospectively analyzed the data of 92 patients (126 ureters) having a diagnosis of malignant extrinsic ureteral obstruction treated with indwelling ureteral stents (polymeric and full-length metallic stents). Of these patients, 35 (54 ureters) were treated with polymeric stents and 57 (72 ureters) with a Resonance® metallic stent. The observation period was censored to 1 year. Survival rate in cases of malignant ureteral obstruction was calculated, and the relationship between the causes of ureteral obstruction, the stent type, and the patency rate was evaluated.ResultsThe median observation period was 145 days, with a median survival time of 258 days. The stent patency rate was 70.9% at 1 year, regardless of stent type. Stent occlusion was observed in 20 patients (33 ureters). According to stent type, occlusion of the polymeric and metallic stents was identified in 12 (22%) and 8 (11%) cases, respectively. The clinical features associated with stent failure were assessed. In univariate analysis, the patency rate was significantly better for the metallic stent than for the polymeric stent (1-year patency rate; 78.4%, 61.1%, respectively, HR, 2.15; 95% CI, 1.07–4.33; p=0.031). However, the patency rate among patients with abdominal dissemination, lymph node metastasis, and direct compression by tumor was not significantly different.ConclusionIndwelling ureteral stents, particularly metallic stents, are effective for the treatment of malignant ureteral obstruction.

The resonance® metallic ureteral stent in the treatment of malignant ureteral obstruction: a prospective observational study

“…Our present findings demonstrated that the treatment success rate for MUO was 77.3% at 6 months and 70.3% at 1 year; these results are similar to those of previous reports [10, 30, 31]. It has also been observed that stent replacement is not necessary in most MUO cases, as we also observed herein.…”

In vivo urinary compatibility of Mg-Sr-Ag alloy in swine model

“…Therefore, to a biodegradable ureteral stent, the primary objective is to assure sufficient mechanical properties during the whole degradation process. Among various mechanical properties, tensile strength and elongation are the most crucial parameters to determine the support performance of the stent [ 10 , 33 , 34 ]. Combining our experimental observation on the tensile behavior with the fracture morphology analysis enables to rationalize the fracture process ( Fig.…”

Bilateral Ureteral Obstruction Related to Pelvic Rhabdomyosarcoma Presenting with Acute Kidney Injury: A Case Report

“…There were some differences in the reports on cancers that cause malignant ureteral obstruction. In adults, ad vanced carcinoma of the stomach, colon, and the gyneco logic and urologic systems were the common neoplasms 7,8) . Based on these studies, gastrointestinal cancer was considered to be the most common cause of malignant ureteral obstruction in adults.…”